Exelixis (EXEL) News Today $34.65 +0.24 (+0.70%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Ontario Teachers Pension Plan Board Reduces Position in Exelixis, Inc. (NASDAQ:EXEL)Ontario Teachers Pension Plan Board trimmed its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 70.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,823 shares of the biotechnology company's stock after sNovember 21 at 5:53 AM | marketbeat.comZacks.com featured highlights Amazon, Maplebear, Exelixis and DoximityNovember 20 at 1:03 PM | finance.yahoo.comEULAV Asset Management Sells 45,000 Shares of Exelixis, Inc. (NASDAQ:EXEL)EULAV Asset Management lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 8.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 500,000 shares of the biotechnology company's stockNovember 20 at 8:42 AM | marketbeat.comInsider Selling: Exelixis, Inc. (NASDAQ:EXEL) EVP Sells 41,588 Shares of StockNovember 20 at 5:31 AM | insidertrades.comJanney Montgomery Scott LLC Cuts Position in Exelixis, Inc. (NASDAQ:EXEL)Janney Montgomery Scott LLC decreased its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 48.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 30,399 shares of the biotechnology company's stock after selling 28,418 shares dNovember 18 at 3:14 AM | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Seizert Capital Partners LLCSeizert Capital Partners LLC boosted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 8.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 469,940 shares of the bioteNovember 17, 2024 | marketbeat.comCornercap Investment Counsel Inc. Reduces Stake in Exelixis, Inc. (NASDAQ:EXEL)Cornercap Investment Counsel Inc. lessened its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 50.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 24,903 shares of the biotechnology company'sNovember 16, 2024 | marketbeat.comEntropy Technologies LP Invests $475,000 in Exelixis, Inc. (NASDAQ:EXEL)Entropy Technologies LP purchased a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 18,300 shares of the biotechnology company's stock, valuedNovember 16, 2024 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Receives Average Recommendation of "Moderate Buy" from BrokeragesExelixis, Inc. (NASDAQ:EXEL - Get Free Report) has been given an average rating of "Moderate Buy" by the twenty analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and fourteen have issued aNovember 16, 2024 | marketbeat.comPrincipal Financial Group Inc. Reduces Position in Exelixis, Inc. (NASDAQ:EXEL)Principal Financial Group Inc. lowered its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 31.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 665,742 shares of the biotechnology company's stock aNovember 15, 2024 | marketbeat.comCWA Asset Management Group LLC Buys New Stake in Exelixis, Inc. (NASDAQ:EXEL)CWA Asset Management Group LLC acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 22,222 shares of the biotechnology company's stock, valuedNovember 12, 2024 | marketbeat.comLos Angeles Capital Management LLC Increases Holdings in Exelixis, Inc. (NASDAQ:EXEL)Los Angeles Capital Management LLC boosted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 124.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,790,855 shares of the biotechnolNovember 10, 2024 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Shares Acquired by Van ECK Associates CorpVan ECK Associates Corp increased its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 66.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 173,584 shares of the biotechnology company'sNovember 9, 2024 | marketbeat.comInsider Selling: Exelixis, Inc. (NASDAQ:EXEL) EVP Sells 96,986 Shares of StockNovember 8, 2024 | insidertrades.comRobeco Institutional Asset Management B.V. Buys 350,026 Shares of Exelixis, Inc. (NASDAQ:EXEL)Robeco Institutional Asset Management B.V. raised its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 263.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 483,064 shares of the biotechnology company's stock after buyNovember 7, 2024 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Director George Poste Sells 30,000 SharesNovember 6, 2024 | insidertrades.comAlameda company Exelixis puts more than 200,000 square feet up for subleaseNovember 5, 2024 | bizjournals.comExelixis (NASDAQ:EXEL) Sets New 52-Week High - Time to Buy?Exelixis (NASDAQ:EXEL) Sets New 52-Week High - Should You Buy?November 5, 2024 | marketbeat.comCapital Management Corp VA Increases Position in Exelixis, Inc. (NASDAQ:EXEL)Capital Management Corp VA increased its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 7.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 365,270 shares of the biotechnology company's stock after acquiringNovember 5, 2024 | marketbeat.com3 Magnificent Stocks Under $100 to Buy in NovemberNovember 3, 2024 | fool.comNew York State Teachers Retirement System Raises Stake in Exelixis, Inc. (NASDAQ:EXEL)New York State Teachers Retirement System increased its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 4.8% during the third quarter, according to its most recent filing with the SEC. The fund owned 439,222 shares of the biotechnology company's stock after buying an additional 20,008 sharesNovember 3, 2024 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) EVP Sells $36,486.80 in StockNovember 2, 2024 | insidertrades.comExelixis (NASDAQ:EXEL) Announces Quarterly Earnings ResultsExelixis (NASDAQ:EXEL - Get Free Report) issued its quarterly earnings results on Tuesday. The biotechnology company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.36 by $0.04. The company had revenue of $539.50 million for the quarter, compared to the consensus estimate of $490.31 million. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The firm's revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.10 EPS.November 1, 2024 | marketbeat.comExelixis, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting NextNovember 1, 2024 | finance.yahoo.comExelixis, Inc. (NASDAQ:EXEL) Holdings Lowered by Stephens Investment Management Group LLCStephens Investment Management Group LLC trimmed its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 1.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,806,564 shares of the biotechnolNovember 1, 2024 | marketbeat.comExelixis: Q3 Earnings SnapshotOctober 31, 2024 | sfgate.comExelixis (EXEL) Receives a Buy from Wells FargoOctober 31, 2024 | markets.businessinsider.comExelixis price target raised to $36 from $29 at BMO CapitalOctober 31, 2024 | markets.businessinsider.comExelixis, Inc. (NASDAQ:EXEL) EVP Jeffrey Hessekiel Sells 25,000 SharesOctober 31, 2024 | insidertrades.comExelixis price target raised to $38 from $33 at TruistOctober 31, 2024 | markets.businessinsider.comDekaBank Deutsche Girozentrale Buys 30,000 Shares of Exelixis, Inc. (NASDAQ:EXEL)DekaBank Deutsche Girozentrale lifted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 7.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 429,690 shares of the biotechnology company's stock after acquirOctober 31, 2024 | marketbeat.comStephens Boosts Exelixis (NASDAQ:EXEL) Price Target to $29.00Stephens raised their price objective on shares of Exelixis from $23.00 to $29.00 and gave the company an "equal weight" rating in a research report on Wednesday.October 30, 2024 | marketbeat.comExelixis' (EXEL) Outperform Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada reissued an "outperform" rating and set a $34.00 target price on shares of Exelixis in a research note on Wednesday.October 30, 2024 | marketbeat.comExelixis (NASDAQ:EXEL) Hits New 1-Year High Following Analyst UpgradeExelixis (NASDAQ:EXEL) Hits New 52-Week High on Analyst UpgradeOctober 30, 2024 | marketbeat.comFY2024 EPS Estimates for Exelixis Lowered by Leerink PartnrsExelixis, Inc. (NASDAQ:EXEL - Free Report) - Stock analysts at Leerink Partnrs dropped their FY2024 earnings estimates for shares of Exelixis in a research note issued on Monday, October 28th. Leerink Partnrs analyst A. Berens now expects that the biotechnology company will post earnings of $1.57October 30, 2024 | marketbeat.comExelixis' Sales, Earnings Surge in Q3October 30, 2024 | fool.comExelixis, Inc. 2024 Q3 - Results - Earnings Call PresentationOctober 29, 2024 | seekingalpha.comChina Universal Asset Management Co. Ltd. Buys 20,641 Shares of Exelixis, Inc. (NASDAQ:EXEL)China Universal Asset Management Co. Ltd. boosted its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 60.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,863 shares of the biotechnology company's stocOctober 29, 2024 | marketbeat.comWhat is Leerink Partnrs' Estimate for Exelixis Q4 Earnings?Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Investment analysts at Leerink Partnrs cut their Q4 2024 earnings estimates for Exelixis in a report issued on Monday, October 28th. Leerink Partnrs analyst A. Berens now expects that the biotechnology company will post earnings of $0.35 per share forOctober 29, 2024 | marketbeat.comEarnings Preview: ExelixisOctober 29, 2024 | benzinga.comAssenagon Asset Management S.A. Sells 588,870 Shares of Exelixis, Inc. (NASDAQ:EXEL)Assenagon Asset Management S.A. lessened its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 34.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,111,358 shares of the biotechnology company's stock afterOctober 26, 2024 | marketbeat.comAllspring Global Investments Holdings LLC Sells 279,296 Shares of Exelixis, Inc. (NASDAQ:EXEL)Allspring Global Investments Holdings LLC trimmed its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 24.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 858,004 shares of the biotechnology company's sOctober 25, 2024 | marketbeat.com1 No-Brainer Stock to Buy With $40October 23, 2024 | fool.comExelixis price target raised to $34 from $27 at TD CowenOctober 22, 2024 | markets.businessinsider.comExelixis, Inc. (NASDAQ:EXEL) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) have received an average rating of "Moderate Buy" from the sixteen ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have given aOctober 22, 2024 | marketbeat.comExelixis (NASDAQ:EXEL) Price Target Raised to $34.00TD Cowen increased their price target on Exelixis from $27.00 to $34.00 and gave the stock a "buy" rating in a research note on Monday.October 21, 2024 | marketbeat.comFriedenthal Financial Buys Shares of 28,674 Exelixis, Inc. (NASDAQ:EXEL)Friedenthal Financial bought a new position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 28,674 shares of the biotechnology company's stock, valued at approximately $744,000.October 19, 2024 | marketbeat.comExelixis Stays Strong With Cabometyx While New Assets Approach Key TrialsOctober 18, 2024 | seekingalpha.comExelixis (NASDAQ:EXEL) Upgraded by The Goldman Sachs Group to Strong SellThe Goldman Sachs Group upgraded Exelixis to a "strong sell" rating in a report on Tuesday.October 18, 2024 | marketbeat.comExelixis: Navigating Patent Challenges and Future Growth Prospects with a Hold RatingOctober 17, 2024 | markets.businessinsider.com Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention. 👉 Click here to access your FREE report now! EXEL Media Mentions By Week EXEL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EXEL News Sentiment▼0.980.46▲Average Medical News Sentiment EXEL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EXEL Articles This Week▼108▲EXEL Articles Average Week Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Medpace News Charles River Laboratories International News ICON Public News National Research News Precigen News Luna Innovations News Alnylam Pharmaceuticals News Biogen News United Therapeutics News Incyte News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EXEL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exelixis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EXEL Stock Alerts